STADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson?s disease
- 02/10/2020
- Press Release
- STADA is submitting approval applications to launch the new therapy in major European markets. Approvals are already in place in Sweden, Denmark, Norway and Finland.
- By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.
- STADA CEO Peter Goldschmidt: ?This acquisition of Lobsor significantly expands STADA?s specialty footprint and serves as further evidence that STADA is a leading go-to-partner for specialty pharmaceuticals, generics and consumer health products. It also complements our portfolio and expertise in the treatment of late-stage Parkinson?s disease, where we have strong expertise via our company Britannia Pharmaceuticals.?